Cadrenal Therapeutics Stock (NASDAQ:CVKD)
Previous Close
$11.30
52W Range
$8.74 - $22.90
50D Avg
$13.17
200D Avg
$14.46
Market Cap
$22.92M
Avg Vol (3M)
$24.41K
Beta
0.98
Div Yield
-
CVKD Company Profile
Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel therapy with orphan drug indication for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.